Home / Companies / ARGX / Catalysts / Page 2 Catalysts · ARGX · CIK 1697862 · page 2 of 2 ARGX catalysts and FDA events, page 2. Updated November 16, 2026 Snapshot 20261116T222116Z Built 2026-11-16 22:21 UTC
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on ARGX PDUFA dates and upcoming catalysts . This page continues the list.
Past catalysts and FDA decisions (continued) Date Drug Company Event Indication Status Source August 25, 2025 — ARGX Topline readout — Positive SEC 8-K Exhibit 99.1 July 2, 2025 efgartigimod iv ARGX Primary completion Lupus Nephritis Completed ClinicalTrials.gov 2H 2025Half-year disclosed empasiprubart (ARGX-117) ARGX Topline readout — Scheduled SEC 8-K Exhibit 99.1 2H 2025Half-year disclosed adimanebart (ARGX-119) ARGX Topline readout — Scheduled SEC 8-K Exhibit 99.1 June 30, 2025 efgartigimod iv ARGX Primary completion Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized Completed ClinicalTrials.gov April 10, 2025 Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ARGX Label expansion — Approved openFDA Drugs@FDA April 10, 2025 VYVGART (efgartigimod) ARGX PDUFA date — Approved SEC 8-K Exhibit 99.1 April 10, 2025 VYVGART (efgartigimod) ARGX FDA approval — Approved SEC 8-K Exhibit 99.1 April 10, 2025 Vyvgart (efgartigimod alfa) ARGX FDA approval — Approved SEC 8-K Exhibit 99.1 April 10, 2025 — ARGX PDUFA date — Scheduled SEC 8-K Exhibit 99.1 1H 2025Half-year disclosed empasiprubart (ARGX-117) ARGX Trial start — Scheduled SEC 8-K Exhibit 99.1 August 8, 2024 Vyvgart (efgartigimod alfa) ARGX Label expansion — Approved openFDA Drugs@FDA August 8, 2024 Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ARGX Label expansion — Approved openFDA Drugs@FDA June 21, 2024 Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ARGX Label expansion — Approved openFDA Drugs@FDA June 21, 2024 VYVGART (efgartigimod) ARGX FDA approval — Approved SEC 8-K Exhibit 99.1 Jul 2023Month disclosed Vyvgart (efgartigimod alfa) ARGX Topline readout — Positive SEC 8-K Exhibit 99.1 June 20, 2023 Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) ARGX FDA approval — Approved openFDA Drugs@FDA March 22, 2022 VYVGART (efgartigimod) ARGX Topline readout gMG Met primary endpoint SEC 8-K Exhibit 99.1 December 17, 2021 Vyvgart (efgartigimod alfa) ARGX FDA approval — Approved openFDA Drugs@FDA
FDA calendar PDUFA dates PDUFA calendar AdCom calendar FDA approvals today CRL tracker PDUFA outcomes dataset Indications Every catalyst is quoted from ARGX’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.